Stephen A. Douglas
#183,766
Most Influential Person Now
Stephen A. Douglas's AcademicInfluence.com Rankings
Stephen A. Douglasphilosophy Degrees
Philosophy
#11679
World Rank
#16129
Historical Rank
Logic
#8482
World Rank
#10621
Historical Rank
Stephen A. Douglasbiology Degrees
Biology
#15426
World Rank
#19399
Historical Rank
Molecular Biology
#2657
World Rank
#2698
Historical Rank
Biochemistry
#2706
World Rank
#2890
Historical Rank
Download Badge
Philosophy Biology
Stephen A. Douglas's Degrees
- Doctorate Medicine Stanford University
Why Is Stephen A. Douglas Influential?
(Suggest an Edit or Addition)Stephen A. Douglas's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 (1999) (779)
- Congestive heart failure and expression of myocardial urotensin II (2002) (259)
- The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects (2007) (242)
- Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey (2000) (230)
- A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. (1994) (212)
- Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. (2000) (191)
- Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries (2000) (181)
- Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. (1993) (171)
- SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. (1994) (162)
- Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat (2000) (160)
- Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. (1996) (156)
- Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. (2001) (156)
- From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. (2004) (150)
- Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. (2004) (133)
- Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey (2002) (129)
- Signal transduction mechanisms mediating the vascular actions of endothelin. (1997) (128)
- Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells (2006) (117)
- Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation (2009) (107)
- Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma (2002) (106)
- Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators (2004) (106)
- The role of endothelin in the pathogenesis of Chagas' disease. (2001) (103)
- Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? (2003) (96)
- Novel receptor antagonists welcome a new era in endothelin biology. (1994) (95)
- Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production (2007) (91)
- Vascular activities of endothelin‐1 and some alanyl substituted analogues in resistance beds of the rat (1989) (90)
- Endothelin‐1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology (1993) (79)
- Expression of urotensin-II in human coronary atherosclerosis (2005) (78)
- Myocardial expression of endothelin-1 in murine Trypanosoma cruzi infection. (2000) (78)
- Central effects of urotensin-II following ICV administration in rats (2001) (75)
- Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. (1999) (74)
- Urotensin II and renal function in the rat. (2006) (73)
- NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation (2013) (65)
- p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension (2003) (65)
- Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice (2003) (65)
- Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. (2006) (63)
- Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein (1995) (63)
- Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. (2004) (62)
- Endothelium‐dependent vascular activities of endothelin‐like peptides in the isolated superior mesenteric arterial bed of the rat (1990) (56)
- Endothelin‐1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ‐123 (1993) (56)
- Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease (2006) (55)
- Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. (1993) (55)
- Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase. (2013) (55)
- Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. (2001) (54)
- A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. (2005) (54)
- The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors (2003) (53)
- Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375 (2005) (53)
- Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist (2002) (52)
- Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670. (1994) (52)
- Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. (2000) (51)
- Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. (1995) (50)
- BQ‐123, a selective endothelin subtype A‐receptor antagonist, lowers blood pressure in different rat models of hypertension (1994) (48)
- Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses. (1992) (48)
- P2X1 stimulation promotes thrombin receptor‐mediated platelet aggregation (2006) (46)
- Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines (2004) (44)
- Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. (1993) (44)
- Trypanosoma cruzi induces endothelin release from endothelial cells. (1995) (44)
- Erosive gastritis and gastrointestinal bleeding in a female runner. Prevention of the bleeding and healing of the gastritis with H2-receptor antagonists. (1987) (43)
- Effect of human urotensin-II infusion on hemodynamics and cardiac function. (2003) (42)
- Dendroaspis Natriuretic Peptide Binds to the Natriuretic Peptide Clearance Receptor: Pharmacological Characterization and Therapeutic Implications: P205 (2006) (42)
- Urotensin-II: a novel systemic hypertensive factor in the cat (2004) (41)
- Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease. (2002) (40)
- Clinical development of endothelin receptor antagonists. (1997) (40)
- The putative mechanistic basis for the modulatory role of endothelin-1 in the altered vascular tone induced by Trypanosoma cruzi. (1999) (39)
- Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. (1995) (38)
- Endothelium‐dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16–21) and other endothelin‐related peptides in the rat (1991) (38)
- The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems (2006) (36)
- In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP‐803) (2006) (33)
- Human urotensin‐II is a potent spasmogen of primate airway smooth muscle (2000) (32)
- Role of p38 MAP kinase in postcapillary venule leukocyte adhesion induced by ischemia/reperfusion injury. (2005) (29)
- Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. (2004) (28)
- Use of differential display to identify differentially expressed mRNAs induced by rat carotid artery balloon angioplasty. (1995) (28)
- Rosiglitazone Protects against Ischemia/Reperfusion-Induced Leukocyte Adhesion in the Zucker Diabetic Fatty Rat (2005) (27)
- Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction. (1994) (27)
- Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues (2008) (26)
- Endothelial modulation and changes in endothelin pressor activity during hypoxia in the rat isolated perfused superior mesenteric arterial bed (1991) (25)
- Pharmacologic Evidence for the Presence of Three Functional Endothelin Receptor Subtypes in Rabbit Saphenous Vein (1995) (24)
- Differential levels of “urotensin-II-like” activity determined by radio-receptor and radioimmuno-assays (2004) (23)
- Pressor Effects of Endothelin‐1 and Some Analogs in the Perfused Superior Mesenteric Arterial Bed of the Rat (1989) (23)
- Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet. (2009) (21)
- Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. (2004) (21)
- Temporal Expression of ECE‐1, ET‐1, ET‐3, ETA, and ETB Receptor mRNAs After Balloon Angioplasty in the Rat (1995) (21)
- Trypanosoma cruzi infection (Chagas' disease) of mice causes activation of the mitogen-activated protein kinase cascade and expression of endothelin-1 in the myocardium. (2000) (20)
- In vivo pharmacological characterization of the non‐peptide endothelin receptor antagonist SB 209670 (1995) (20)
- Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy (2010) (19)
- Endothelin Receptor Subtypes in the Pathogenesis of Angioplasty‐Induced Neointima Formation in the Rat: A Comparison of Selective ETA Receptor Antagonism and Dual ETA/ETB Receptor Antagonism Using BQ‐123 and SB 209670 (1995) (19)
- Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). (2005) (18)
- Responses to endothelin-1, human proendothelin (1–38) and porcine proendothelin (1–39) in the rat on intravenous administration and in the blood perfused mesentery (1991) (18)
- Chapter 11. Urotensin-II receptor modulators (2003) (18)
- Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. (2005) (17)
- Phosphoramidon treatment improves the consequences of chagasic heart disease in mice. (2002) (16)
- Techniques: Cardiovascular pharmacology and drug discovery in the 21st century. (2004) (16)
- Urotensin II evokes neurotransmitter release from rat cerebrocortical slices (2008) (15)
- Identification and characterization of binding sites for human urotensin-II in Sprague–Dawley rat renal medulla using quantitative receptor autoradiography (2006) (15)
- N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists. (2008) (14)
- Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium (2009) (14)
- Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice. (2000) (14)
- Molecular cloning and pharmacological characterization of bovine calcitonin receptor-like receptor from bovine aortic endothelial cells. (2002) (14)
- Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. (2008) (14)
- 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists. (2008) (13)
- Aminomethylpiperazines as selective urotensin antagonists. (2008) (13)
- Direct Inotropic Effects of Exogenous and Endogenous Urotensin-IICLINICAL PERSPECTIVE (2009) (13)
- Heme-oxygenase induction inhibits arteriolar thrombosis in vivo: effect of the non-substrate inducer cobalt protoporphyrin. (2009) (13)
- Meeting reportClinical development of endothelin receptor antagonists (1997) (12)
- Urotensin II Receptor Knockout Mice on an ApoE Knockout Background Fed a High-Fat Diet Exhibit an Enhanced Hyperlipidemic and Atherosclerotic Phenotype (2009) (12)
- Non-peptidic urotensin-II receptor modulators (2006) (11)
- Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083. (1998) (11)
- SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog. (1998) (11)
- erratum: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 (1999) (10)
- Development of potent and selective small-molecule human Urotensin-II antagonists. (2008) (9)
- Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles. (2008) (9)
- The Effects of Benzodiazepines on Urotensin II-Stimulated Norepinephrine Release from Rat Cerebrocortical Slices (2009) (9)
- Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. (2005) (7)
- Agonist‐Dependent Inhibition by Peptide and Nonpeptide Endothelin Receptor Antagonists in the Rabbit Isolated Pulmonary Artery (1995) (6)
- Differential modulation of endothelin ligand‐induced contraction in isolated tracheae from endothelin B (ETB) receptor knockout mice (2001) (6)
- Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II. (2003) (5)
- Vascular and Cardiac Effects of Endothelin (2001) (4)
- Quantitative analysis of orphan G protein-coupled receptor mRNAs by TaqMan Real-Time PCR: G2A and GPR4 lysophospholipid receptor expression in leukocytes and in a rat myocardial infarction-heart failure model. (2005) (2)
- Erratum to “Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas’ disease” [Int. J. Parasitol. 32(12) (2002) 1497–1506] (2003) (2)
- Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Non-Failing Human Myocardium (2008) (1)
- Abstract 1519: Urotensin-II Receptor Knockout Increases Plasma Lipids and Atherosclerosis in ApoE Knockout Mice (2006) (1)
- Vascular Smooth Muscle Function in Rats with Acute Renal Failure (1989) (1)
- Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting (2007) (1)
- The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure: A Pharmaceutical Industry Perspective (2010) (0)
- Abstract 867: In vivo Inhibition of p38 MAPK Attenuates Angiotensin II-Induced Superoxide Anion Production and Target Organ Damage through Suppression of NAD(P)H Oxidase (2006) (0)
- Blockade of the Urotensin II Receptor Does Not Attenuate Cardiac Remodelling in a Model of Pressure-Overload Hypertrophy: Functional and Histological Assessment (2008) (0)
- Soluble Epoxide Hydrolase Inhibitors Attenuate Cardiomyocyte Hypertrophy and Cardiofibroblast Collagen Synthesis via JNK and NFκB Pathway (2009) (0)
- Vascular activities ofendothelin- 1andsomealanyl substituted analogues inresistance bedsoftherat (1989) (0)
- Th-W61:1 Urotensin-II receptor knockout increases plasma total cholesterol and atherosclerosis in ApoE knockout mice (2006) (0)
- Mechanistic basis of trypanosoma cruzi induced alterations in vascular tone (1997) (0)
- The use of differential display to demonstrate enhanced expression of protein kinase C14-3 3-gamma mRNA following rat carotid artery balloon angioplasty (1994) (0)
- Endothelium-dependent modulation of the pressor actions of endothelin/sarafotoxin peptides in the isolated rat superior mesenteric arterial bed (1990) (0)
- Abstract 5256: Identification of a Novel Epoxyeicosatrienoic Acid (EET) Receptor: EETs Function as Selective, Endogenous Thromboxane Receptor Antagonists (2008) (0)
- Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
- Urotensin receptor in GtoPdb v.2021.3 (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stephen A. Douglas?
Stephen A. Douglas is affiliated with the following schools:
